These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 33016343)

  • 1. Letter to the Editor: Tenofovir vs. Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection.
    Yuan G; Yao J; Yu J; Xie X; He S
    Hepatology; 2021 Mar; 73(3):1240. PubMed ID: 33016343
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter to the Editor: Re: Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection.
    Kim BK; Kim SU
    Hepatology; 2021 Jan; 73(1):466. PubMed ID: 32602169
    [No Abstract]   [Full Text] [Related]  

  • 3. Antiviral therapy after curative treatment of hepatocellular carcinoma in patients with chronic hepatitis B infection: Is tenofovir or entecavir preferred?
    van Erpecum KJ; Sonneveld MJ
    Eur J Intern Med; 2021 Jul; 89():27-29. PubMed ID: 34023149
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of nucleoside and nucleotide analogs in the recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection: A multicenter study.
    Qi W; Shen J; Dai J; Wu Y; Zhang Y; Leng S; Gao F; Ran S; Peng W; Zhang X; Wen T; Li C
    Cancer Med; 2021 Dec; 10(23):8421-8431. PubMed ID: 34643050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tenofovir vs. entecavir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative resection.
    Wang XH; Hu ZL; Fu YZ; Hou JY; Li WX; Zhang YJ; Xu L; Zhou QF; Chen MS; Zhou ZG
    J Gastroenterol; 2022 Mar; 57(3):185-198. PubMed ID: 35152312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma.
    Lee JH; Kim BK; Park SY; Tak WY; Park JY; Kim DY; Ahn SH; Sinn DH; Kim SU
    Eur J Intern Med; 2021 Jul; 89():48-55. PubMed ID: 33810942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Letter: tenofovir versus entecavir for hepatocellular carcinoma prevention in chronic hepatitis B-related compensated cirrhosis.
    Huang R; Liu J; Wang J; Wu C
    Aliment Pharmacol Ther; 2021 May; 53(9):1040-1041. PubMed ID: 33831236
    [No Abstract]   [Full Text] [Related]  

  • 8. Letter: tenofovir may be superior to entecavir for treatment-naïve chronic hepatitis B patients.
    Wang JG; Chen R; Wang LC
    Aliment Pharmacol Ther; 2021 May; 53(9):1048-1049. PubMed ID: 33831238
    [No Abstract]   [Full Text] [Related]  

  • 9. Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection.
    Choi J; Jo C; Lim YS
    Hepatology; 2021 Feb; 73(2):661-673. PubMed ID: 32324905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of tenofovir and entecavir use with prognosis after surgical resection for hepatitis B virus-related hepatocellular carcinoma.
    Yun B; Ahn SH; Oh J; Yoon JH; Kim BK
    Eur J Intern Med; 2022 Sep; 103():122-125. PubMed ID: 35835625
    [No Abstract]   [Full Text] [Related]  

  • 11. Letter: tenofovir versus entecavir for hepatocellular carcinoma prevention in chronic hepatitis B-related compensated cirrhosis-authors' reply.
    Chiu SY; Chang KC; Hu TH; Chien RN
    Aliment Pharmacol Ther; 2021 May; 53(9):1042-1043. PubMed ID: 33831240
    [No Abstract]   [Full Text] [Related]  

  • 12. Letter: tenofovir may be superior to entecavir for treatment-naïve chronic hepatitis B patients-authors' reply.
    Pol S; Lusivika Nzinga C; Carrat F
    Aliment Pharmacol Ther; 2021 May; 53(9):1050. PubMed ID: 33831235
    [No Abstract]   [Full Text] [Related]  

  • 13. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.
    Kim SU; Seo YS; Lee HA; Kim MN; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
    J Hepatol; 2019 Sep; 71(3):456-464. PubMed ID: 30959156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Entecavir and tenofovir reduce hepatitis B virus-related hepatocellular carcinoma recurrence more effectively than other antivirals.
    Cho H; Ahn H; Lee DH; Lee JH; Jung YJ; Chang Y; Nam JY; Cho YY; Lee DH; Cho EJ; Yu SJ; Lee JM; Kim YJ; Yoon JH
    J Viral Hepat; 2018 Jun; 25(6):707-717. PubMed ID: 29316069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tenofovir vs. Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma after Radiofrequency Ablation.
    Hu Z; Zeng H; Hou J; Wang J; Xu L; Zhang Y; Chen M; Zhou Z
    Viruses; 2022 Mar; 14(4):. PubMed ID: 35458386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma.
    Lee SW; Choi J; Kim SU; Lim YS
    Clin Mol Hepatol; 2021 Jul; 27(3):402-412. PubMed ID: 34157830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B.
    Lee HA; Seo YS; Kim SU
    Gastroenterology; 2020 Jun; 158(8):2310-2311. PubMed ID: 32201178
    [No Abstract]   [Full Text] [Related]  

  • 18. Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis.
    Goyal SK; Dixit VK; Shukla SK; Ghosh J; Behera M; Tripathi M; Gupta N; Ranjan A; Jain AK
    Indian J Gastroenterol; 2015 Jul; 34(4):286-91. PubMed ID: 26243587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir Treatment for Chronic Hepatitis B Virus: A Reconstructed Individual Patient Data Meta-analysis.
    Tan DJH; Ng CH; Tay PWL; Syn N; Muthiah MD; Lim WH; Tang ASP; Lim KE; Lim GEH; Tamaki N; Kim BK; Teng MLP; Fung J; Loomba R; Nguyen MH; Huang DQ
    JAMA Netw Open; 2022 Jun; 5(6):e2219407. PubMed ID: 35767258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tenofovir versus entecavir in prevention of hepatocellular carcinoma and mortality in patients with chronic hepatitis B.
    Kamal F; Khan MA; Ahmed A; Nair S
    Gut; 2020 Nov; 69(11):2054-2056. PubMed ID: 32041745
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.